NEWS ANNOUNCEMENTS

In September 2022, Prokardia received a $750,000 Targeted Translation Research Accelerator Grant from MTPConnect, Australia's Growth Centre for the medical technologies, biotechnologies and pharmaceuticals sector.  Formed in December 2015 as part of the Federal Government’s Industry Growth Centres Initiative, MTPConnect is an independent, not-for-profit organisation.

 

MTPConnect is forging stronger connections between research and industry to help maximise opportunities for Australians to not only make scientific and technological breakthroughs, but to see them developed through the proof-of-concept stage and successfully translated and commercialised.

In November 2022, Prokardia received a $500,000 Stage 1 grant from CUREator.  ​Delivered by Brandon BioCatalyst, CUREator is backed by the Australian Federal Government’s Medical Research Future Fund. The MRFF’s $80 million Medical Research Commercialisation Initiative aims to support early-stage health and medical research and innovation in Australia through to proof-of-concept and beyond, providing opportunities for commercialisation. 

 

CUREator is responsible for managing a $40m portion of this fund, dedicated to supporting novel therapeutics and preclinical medical research.  If Prokardia achieves positive in vivo data in its various P2X7 cardio vascular models, then the Company will apply for the Stage 2 CUREator grant, which supports the development of clinical-stage therapeutics.